IRONWOOD PHARMACEUTICALS, INC. Operating Income
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Operating Income of $79.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-06-30 was $79.31M, a 74.99% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2026-03-31 was $72.57M.
- IRONWOOD PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-12-31 was $6.80M, a 78.39% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. operating income (loss) for the quarter ending 2025-09-30 was $75.48M, a 194.45% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. operating income (loss) for fiscal 2025 was $98.50M, a 5.78% increase from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. operating income (loss) for fiscal 2024 was $93.12M.
- IRONWOOD PHARMACEUTICALS, INC. operating income (loss) for fiscal 2023 was -$945.43M, a 477.66% decline from fiscal 2022.
- IRONWOOD PHARMACEUTICALS, INC. operating income (loss) for fiscal 2022 was $250.34M, a 7.78% increase from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $79.31M 10-Q · filed 2026-08-06 | $151.88M 10-Q · filed 2026-08-06 | $158.69M derived: sum of 3 quarters · filed 2026-08-06 | $234.17M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $72.57M 10-Q · filed 2026-05-07 | $79.38M derived: sum of 2 quarters · filed 2026-05-07 | $154.86M derived: sum of 3 quarters · filed 2026-05-07 | $200.18M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $6.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $82.29M derived: sum of 2 quarters · filed 2026-02-26 | $127.61M derived: sum of 3 quarters · filed 2026-08-06 | $98.50M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $75.48M 10-Q · filed 2025-11-10 | $120.81M derived: sum of 2 quarters · filed 2026-08-06 | $91.70M 10-Q · filed 2025-11-10 | $123.19M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $45.32M 10-Q · filed 2026-08-06 | $16.21M 10-Q · filed 2026-08-06 | $47.70M derived: sum of 3 quarters · filed 2026-08-06 | $73.34M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$29.11M 10-Q · filed 2026-05-07 | $2.38M derived: sum of 2 quarters · filed 2026-05-07 | $28.02M derived: sum of 3 quarters · filed 2026-05-07 | $53.00M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $31.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $57.13M derived: sum of 2 quarters · filed 2026-02-26 | $82.10M derived: sum of 3 quarters · filed 2026-02-26 | $93.12M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $25.64M 10-Q · filed 2025-11-10 | $50.61M derived: sum of 2 quarters · filed 2025-11-10 | $61.63M 10-Q · filed 2025-11-10 | $99.22M derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | $24.98M 10-Q · filed 2025-08-11 | $36.00M 10-Q · filed 2025-08-11 | $73.59M derived: sum of 3 quarters · filed 2025-08-11 | $113.61M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | $11.02M 10-Q · filed 2025-05-12 | $48.61M derived: sum of 2 quarters · filed 2025-05-12 | $88.63M derived: sum of 3 quarters · filed 2025-05-12 | -$994.51M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $37.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $77.61M derived: sum of 2 quarters · filed 2025-03-31 | -$1.01B derived: sum of 3 quarters · filed 2025-03-31 | -$945.43M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $40.02M 10-Q · filed 2024-11-07 | -$1.04B derived: sum of 2 quarters · filed 2024-11-07 | -$983.02M 10-Q · filed 2024-11-07 | -$914.66M derived: sum of 4 quarters · filed 2025-03-31 | ||||
| 2023-06-30 | -$1.08B 10-Q · filed 2024-08-08 | -$1.02B 10-Q · filed 2024-08-08 | -$954.68M derived: sum of 3 quarters · filed 2025-03-31 | -$886.21M derived: sum of 4 quarters · filed 2025-03-31 | ||||
| 2023-03-31 | $60.10M 10-Q · filed 2024-05-09 | $128.46M derived: sum of 2 quarters · filed 2025-03-31 | $196.93M derived: sum of 3 quarters · filed 2025-03-31 | $252.59M derived: sum of 4 quarters · filed 2025-03-31 | ||||
| 2022-12-31 | $68.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $136.84M derived: sum of 2 quarters · filed 2025-03-31 | $192.49M derived: sum of 3 quarters · filed 2025-03-31 | $250.34M 10-K · filed 2025-03-31 | ||||
| 2022-09-30 | $68.47M 10-Q · filed 2023-11-09 | $124.13M derived: sum of 2 quarters · filed 2023-11-09 | $181.97M 10-Q · filed 2023-11-09 | $238.57M derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2022-06-30 | $55.66M 10-Q · filed 2023-08-09 | $113.50M 10-Q · filed 2023-08-09 | $170.09M derived: sum of 3 quarters · filed 2024-02-16 | $235.26M derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2022-03-31 | $57.85M 10-Q · filed 2023-05-04 | $114.44M derived: sum of 2 quarters · filed 2024-02-16 | $179.61M derived: sum of 3 quarters · filed 2024-02-16 | $244.71M derived: sum of 4 quarters · filed 2024-02-16 | ||||
| 2021-12-31 | $56.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $121.76M derived: sum of 2 quarters · filed 2024-02-16 | $186.86M derived: sum of 3 quarters · filed 2024-02-16 | $232.26M 10-K · filed 2024-02-16 | ||||
| 2021-09-30 | $65.17M 10-Q · filed 2022-11-03 | $130.27M derived: sum of 2 quarters · filed 2022-11-03 | $175.67M 10-Q · filed 2022-11-03 | $227.05M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-06-30 | $65.10M 10-Q · filed 2022-08-04 | $110.50M 10-Q · filed 2022-08-04 | $161.88M derived: sum of 3 quarters · filed 2023-02-16 | $207.50M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-03-31 | $45.40M 10-Q · filed 2022-05-05 | $96.78M derived: sum of 2 quarters · filed 2023-02-16 | $142.40M derived: sum of 3 quarters · filed 2023-02-16 | $175.11M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2020-12-31 | $51.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $97.00M derived: sum of 2 quarters · filed 2023-02-16 | $129.71M derived: sum of 3 quarters · filed 2023-02-16 | $142.94M 10-K · filed 2023-02-16 | ||||
| 2020-09-30 | $45.62M 10-Q · filed 2021-11-04 | $78.33M derived: sum of 2 quarters · filed 2021-11-04 | $91.56M 10-Q · filed 2021-11-04 | $141.15M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-06-30 | $32.71M 10-Q · filed 2021-08-05 | $45.94M 10-Q · filed 2021-08-05 | $95.53M derived: sum of 3 quarters · filed 2022-02-18 | $161.42M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-03-31 | $13.23M 10-Q · filed 2021-05-06 | $62.82M derived: sum of 2 quarters · filed 2022-02-18 | $128.71M derived: sum of 3 quarters · filed 2022-02-18 | $150.28M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2019-12-31 | $49.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $115.48M derived: sum of 2 quarters · filed 2022-02-18 | $137.06M derived: sum of 3 quarters · filed 2022-02-18 | $120.12M 10-K · filed 2022-02-18 | ||||
| 2019-09-30 | $65.89M 10-Q · filed 2020-11-05 | $87.46M derived: sum of 2 quarters · filed 2020-11-05 | $70.53M 10-Q · filed 2020-11-05 | $100.39M derived: sum of 4 quarters · filed 2021-02-17 | ||||
| 2019-06-30 | $21.58M 10-Q · filed 2020-08-06 | $4.64M 10-Q · filed 2020-08-06 | $34.50M derived: sum of 3 quarters · filed 2021-02-17 | -$112.07M derived: sum of 4 quarters · filed 2021-02-17 | ||||
| 2019-03-31 | -$16.93M 10-Q · filed 2020-05-06 | -$54.37M 10-Q · filed 2019-05-02 | $12.93M derived: sum of 2 quarters · filed 2021-02-17 | -$133.64M derived: sum of 3 quarters · filed 2021-02-17 | -$148.32M derived: sum of 4 quarters · filed 2021-02-17 | |||
| 2018-12-31 | $29.86M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | -$116.71M derived: sum of 2 quarters · filed 2021-02-17 | -$131.39M derived: sum of 3 quarters · filed 2021-02-17 | -$150.67M 10-K · filed 2021-02-17 | -$238.89M 10-K · filed 2019-02-25 | |||
| 2018-09-30 | -$146.57M 10-Q · filed 2019-10-31 | -$169.10M 10-Q · filed 2018-11-06 | -$161.25M derived: sum of 2 quarters · filed 2019-10-31 | -$180.53M 10-Q · filed 2019-10-31 | -$244.89M 10-Q · filed 2018-11-06 | -$112.33M derived: sum of 4 quarters · filed 2020-02-13 | ||
| 2018-06-30 | -$14.68M 10-Q · filed 2019-07-30 | -$39.92M 10-Q · filed 2018-08-06 | -$33.96M 10-Q · filed 2019-07-30 | -$75.79M 10-Q · filed 2018-08-06 | $34.24M derived: sum of 3 quarters · filed 2020-02-13 | $14.81M derived: sum of 4 quarters · filed 2020-02-13 | ||
| 2018-03-31 | -$35.87M 10-Q · filed 2019-05-02 | $48.92M derived: sum of 2 quarters · filed 2020-02-13 | $29.48M derived: sum of 3 quarters · filed 2020-02-13 | -$11.53M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2017-12-31 | $84.79M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $65.35M derived: sum of 2 quarters · filed 2020-02-13 | $24.34M derived: sum of 3 quarters · filed 2020-02-13 | -$15.36M 10-K · filed 2020-02-13 | -$77.39M 10-K · filed 2018-02-22 | |||
| 2017-09-30 | -$19.43M 10-Q · filed 2018-11-06 | -$60.45M derived: sum of 2 quarters · filed 2018-11-06 | -$100.15M 10-Q · filed 2018-11-06 | -$106.45M derived: sum of 4 quarters · filed 2019-02-25 | ||||
| 2017-06-30 | -$41.01M 10-Q · filed 2018-08-06 | -$80.72M 10-Q · filed 2018-08-06 | -$87.02M derived: sum of 3 quarters · filed 2019-02-25 | -$115.30M derived: sum of 4 quarters · filed 2019-02-25 | ||||
| 2017-03-31 | -$39.70M 10-Q · filed 2018-05-04 | -$46.01M derived: sum of 2 quarters · filed 2019-02-25 | -$74.29M derived: sum of 3 quarters · filed 2019-02-25 | -$89.61M derived: sum of 4 quarters · filed 2019-02-25 | ||||
| 2016-12-31 | -$6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | -$34.59M derived: sum of 2 quarters · filed 2019-02-25 | -$49.90M derived: sum of 3 quarters · filed 2019-02-25 | -$51.87M 10-K · filed 2019-02-25 | ||||
| 2016-09-30 | -$28.29M 10-Q · filed 2017-11-02 | -$43.60M derived: sum of 2 quarters · filed 2017-11-02 | -$45.57M 10-Q · filed 2017-11-02 | -$51.40M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-06-30 | -$15.31M 10-Q · filed 2017-08-03 | -$17.28M 10-Q · filed 2017-08-03 | -$23.11M derived: sum of 3 quarters · filed 2018-02-22 | -$49.30M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-03-31 | -$1.97M 10-Q · filed 2017-05-08 | -$7.79M derived: sum of 2 quarters · filed 2018-02-22 | -$33.98M derived: sum of 3 quarters · filed 2018-02-22 | -$75.99M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2015-12-31 | -$5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$32.01M derived: sum of 2 quarters · filed 2018-02-22 | -$74.02M derived: sum of 3 quarters · filed 2018-02-22 | -$102.09M 10-K · filed 2018-02-22 | ||||
| 2015-09-30 | -$26.18M 10-Q · filed 2016-11-07 | -$68.19M derived: sum of 2 quarters · filed 2016-11-07 | -$96.26M 10-Q · filed 2016-11-07 | -$129.39M derived: sum of 4 quarters · filed 2017-02-22 | ||||
| 2015-06-30 | -$42.01M 10-Q · filed 2016-08-08 | -$70.08M 10-Q · filed 2016-08-08 | -$103.20M derived: sum of 3 quarters · filed 2017-02-22 | -$139.94M derived: sum of 4 quarters · filed 2017-02-22 | ||||
| 2015-03-31 | -$28.07M 10-Q · filed 2016-05-10 | -$61.19M derived: sum of 2 quarters · filed 2017-02-22 | -$97.93M derived: sum of 3 quarters · filed 2017-02-22 | -$153.05M derived: sum of 4 quarters · filed 2017-02-22 | ||||
| 2014-12-31 | -$33.13M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | -$69.86M derived: sum of 2 quarters · filed 2017-02-22 | -$124.98M derived: sum of 3 quarters · filed 2017-02-22 | -$169.37M 10-K · filed 2017-02-22 | ||||
| 2014-09-30 | -$36.74M 10-Q · filed 2015-11-05 | -$91.86M derived: sum of 2 quarters · filed 2015-11-05 | -$136.25M 10-Q · filed 2015-11-05 | -$182.98M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-06-30 | -$55.12M 10-Q · filed 2015-08-07 | -$99.51M 10-Q · filed 2015-08-07 | -$146.24M derived: sum of 3 quarters · filed 2016-02-19 | -$202.79M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-03-31 | -$44.39M 10-Q · filed 2015-05-06 | -$91.13M derived: sum of 2 quarters · filed 2016-02-19 | -$147.68M derived: sum of 3 quarters · filed 2016-02-19 | -$207.56M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2013-12-31 | -$46.74M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | -$103.29M derived: sum of 2 quarters · filed 2016-02-19 | -$163.17M derived: sum of 3 quarters · filed 2016-02-19 | -$252.00M 10-K · filed 2016-02-19 | ||||
| 2013-09-30 | -$56.55M 10-Q · filed 2014-11-05 | -$116.43M derived: sum of 2 quarters · filed 2014-11-05 | -$205.26M 10-Q · filed 2014-11-05 | -$249.16M derived: sum of 4 quarters · filed 2015-02-18 | ||||
| 2013-06-30 | -$59.88M 10-Q · filed 2014-08-05 | -$148.71M 10-Q · filed 2014-08-05 | -$192.61M derived: sum of 3 quarters · filed 2015-02-18 | -$145.00M derived: sum of 4 quarters · filed 2015-02-18 | ||||
| 2013-03-31 | -$88.83M 10-Q · filed 2014-04-29 | -$132.73M derived: sum of 2 quarters · filed 2015-02-18 | -$85.13M derived: sum of 3 quarters · filed 2015-02-18 | -$125.96M derived: sum of 4 quarters · filed 2015-02-18 | ||||
| 2012-12-31 | -$43.90M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-18 | $3.71M derived: sum of 2 quarters · filed 2015-02-18 | -$37.13M derived: sum of 3 quarters · filed 2015-02-18 | -$72.76M 10-K · filed 2015-02-18 | ||||
| 2012-09-30 | $47.61M 10-Q · filed 2013-10-28 | $6.77M derived: sum of 2 quarters · filed 2013-10-28 | -$28.86M 10-Q · filed 2013-10-28 | -$35.89M derived: sum of 4 quarters · filed 2014-02-07 | ||||
| 2012-06-30 | -$40.83M 10-Q · filed 2013-08-08 | -$76.47M 10-Q · filed 2013-08-08 | -$83.50M derived: sum of 3 quarters · filed 2014-02-07 | -$105.12M derived: sum of 4 quarters · filed 2014-02-07 | ||||
| 2012-03-31 | -$35.64M 10-Q · filed 2013-04-23 | -$42.67M derived: sum of 2 quarters · filed 2014-02-07 | -$64.28M derived: sum of 3 quarters · filed 2014-02-07 | -$83.24M derived: sum of 4 quarters · filed 2014-02-07 | ||||
| 2011-12-31 | -$7.03M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-07 | -$28.65M derived: sum of 2 quarters · filed 2014-02-07 | -$47.60M derived: sum of 3 quarters · filed 2014-02-07 | -$66.14M 10-K · filed 2014-02-07 | ||||
| 2011-09-30 | -$21.62M 10-Q · filed 2012-11-06 | -$40.57M derived: sum of 2 quarters · filed 2012-11-06 | -$59.11M 10-Q · filed 2012-11-06 | -$71.91M derived: sum of 4 quarters · filed 2013-02-21 | ||||
| 2011-06-30 | -$18.95M 10-Q · filed 2012-08-07 | -$37.49M 10-Q · filed 2012-08-07 | -$50.29M derived: sum of 3 quarters · filed 2013-02-21 | -$66.45M derived: sum of 4 quarters · filed 2013-02-21 | ||||
| 2011-03-31 | -$18.54M 10-Q · filed 2012-05-10 | -$31.34M derived: sum of 2 quarters · filed 2013-02-21 | -$47.50M derived: sum of 3 quarters · filed 2013-02-21 | -$64.81M derived: sum of 4 quarters · filed 2013-02-21 | ||||
| 2010-12-31 | -$12.79M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | -$28.96M derived: sum of 2 quarters · filed 2013-02-21 | -$46.27M derived: sum of 3 quarters · filed 2013-02-21 | -$60.77M 10-K · filed 2013-02-21 | ||||
| 2010-09-30 | -$16.16M 10-Q · filed 2011-11-09 | -$33.48M derived: sum of 2 quarters · filed 2011-11-09 | -$47.97M 10-Q · filed 2011-11-09 | |||||
| 2010-06-30 | -$17.31M 10-Q · filed 2011-08-12 | -$31.81M 10-Q · filed 2011-08-12 | ||||||
| 2009-12-31 | -$60.82M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |